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Abstract
Background: Ionizing irradiation is a commonly accepted treatment modality for lung cancer patients. However, the clinical
outcome is hampered by normal tissue toxicity and tumor hypoxia. Since tumors often have higher levels of active heat
shock protein 90 (Hsp90) than normal tissues, targeting of Hsp90 might provide a promising strategy to sensitize tumors
towards irradiation. Hsp90 client proteins include oncogenic signaling proteins, cell cycle activators, growth factor receptors
and hypoxia inducible factor-1a (HIF-1a). Overexpression of HIF-1a is assumed to promote malignant transformation and
tumor progression and thus might reduce the accessibility to radiotherapy.
Methodology/Principal Findings: Herein, we describe the effects of the novel Hsp90 inhibitor NVP-AUY922 and 17-
allylamino-17-demethoxygeldanamycin (17-AAG), as a control, on HIF-1a levels and radiosensitivity of lung carcinoma cells
under normoxic and hypoxic conditions. NVP-AUY922 exhibited a similar biological activity to that of 17-AAG, but at only 1/
10 of the dose. As expected, both inhibitors reduced basal and hypoxia-induced HIF-1a levels in EPLC-272H lung carcinoma
cells. However, despite a down-regulation of HIF-1a upon Hsp90 inhibition, sensitivity towards irradiation remained
unaltered in EPLC-272H cells under normoxic and hypoxic conditions. In contrast, treatment of H1339 lung carcinoma cells
with NVP-AUY922 and 17-AAG resulted in a significant up-regulation of their initially high HIF-1a levels and a concomitant
increase in radiosensitivity.
Conclusions/Significance: In summary, our data show a HIF-1a-independent radiosensitization of normoxic and hypoxic
H1339 lung cancer cells by Hsp90 inhibition.
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Introduction
Lung cancer is one of the most frequent tumors worldwide and
patients with locoregionally advanced tumor stages are frequently
treated with radiochemotherapy. However, the efficacy of
radiotherapy is limited by genetic and epigenetic diversity [1]
and extrinsic factors such as hypoxia [2,3]. The adaptation of
tumor cells to hypoxia is primarily mediated by stabilization of two
hypoxia inducible factor (HIF) complexes, HIF-1 and HIF-2 [4].
HIF-1 and HIF-2 are heterodimeric transcription factors com-
posed of a constitutively expressed b-subunit (HIF-1b/ARNT) and
a HIF-a subunit (HIF-1a, HIF-2a), which is regulated by tissue
oxygen status. Under normoxia, hydroxylation of the HIF-a
subunit by prolyl hydroxylase domain (PHD) proteins enables
binding of the von Hippel-Lindau tumor suppressor protein (VHL)
that rapidly targets the HIF-a subunit to ubiquitination and
proteasomal degradation. Under hypoxia, the degradation path-
way is suppressed and the HIF-a subunit accumulates, translocates
into the nucleus and dimerizes with the HIF-b subunit. The HIF
complex binds to the hypoxia responsive element (HRE) in the
promoter region of oxygen-regulated genes and leads to their
transcriptional activation. Although the majority of these genes are
involved in the adaptation of tumor cells to hypoxic conditions
(e.g., shift to glycolytic metabolism), a substantial proportion also
contributes to tumor progression by inducing angiogenesis, local
invasion and metastatic dissemination [2].
The HIF-a subunits have been shown to interact with the
molecular chaperone heat shock protein 90 (Hsp90) [5]. Hsp90 is
involved in the posttranslational folding and stabilization of more
than 200 client proteins which are required for the activity of key
regulators of cell signaling that promote tumor cell growth and
radioresistance [6]. Hsp90 is frequently overexpressed in tumors
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31110and therefore, inhibition of Hsp90 has emerged as a potential drug
target in cancer therapy. The first Hsp90 inhibitor that entered
clinical trials up to phase III was 17-allylamino-17-demethox-
ygeldanamycin (17-AAG), a derivative of the natural antibiotic
geldanamycin [6]. Despite its anti-tumor activity, 17-AAG is
hampered by its poor water solubility, toxicity and limited
absorption. The synthetic, isoxazole/ resorcinol-based Hsp90
inhibitor NVP-AUY922 is a second generation Hsp90 inhibitor
which leads to tumor growth inhibition in vitro and regression of
human tumor xenografts in mice [7]. Compared to 17-AAG,
NVP-AUY922 exhibits a tighter binding to Hsp90 and is
metabolically more stable [8]. Due to its improved pharmacoki-
netics and bioavailability, NVP-AUY922 is expected to be more
effective than 17-AAG. Since Hsp90 interferes with a variety of
pathways (including DNA repair [9]) which are known to protect
tumor cells from irradiation-induced death [9,10], Hsp90
inhibition is assumed to improve the outcome of radiotherapy.
Increased levels of HIF-1a or HIF-2a have been associated with
resistance of tumors to irradiation [11,12], although, the role of
Hsp90 inhibitors in the regulation of HIF is not completely
understood. Therefore, we have analyzed the effects of NVP-
AUY922 and 17-AAG on the HIF-1a/HIF-2a expression in
combination with radiosensitivity in lung cancer cell lines under
normoxic and hypoxic conditions.
Results
Hsp90 inhibitors increase HIF-1a levels in H1339 lung
cancer cells
Since Hsp90 co-immunoprecipitates with HIF-a subunits [5],
Hsp90 inhibition has gained attention in targeting hypoxic
signaling. Herein, HIF-1a and HIF-2a protein levels were
analyzed in EPLC-272H and H1339 lung cancer cells under
normoxic ([O2]=21%) and hypoxic ([O2]=0.66%) conditions, in
the presence and absence of two structurally distinct Hsp90
inhibitors, 17-AAG and NVP-AUY922. Under normoxia, EPLC-
272H cells express low levels of HIF-1a (6976117 pg/mg protein)
that are more than doubled following a 24 h hypoxia treatment
(15746286 pg/mg protein). In contrast, H1339 cells exhibit high
basal HIF-1a levels already under normoxic conditions
(15466296 pg/mg protein) which were not further enhanced by
hypoxia (13756282 pg/mg protein). Kinetic studies revealed
significantly increased HIF-1a levels from 2 to 24 h after hypoxia
in EPLC-272H cells (Fig. 1A, black bars, left graph; *p#0.05;
***p#0.001), whereas the high basal HIF-1a levels remained
unaffected in H1339 cells (Fig. 1A, black bars, right graph). As
demonstrated previously, the inability of H1339 cells to up-
regulate HIF-1a in response to hypoxia can neither be explained
by varying cell densities, absence / presence of growth factors nor
by reoxygenation effects [13]. In contrast to HIF-1a, HIF-2a was
up-regulated upon hypoxic exposure in both tumor cell lines
(Fig. 1B). In accordance with findings of other groups [14], G1-
phase was up- and S-phase was down-regulated upon hypoxic
exposure in H1339 cells (Fig. S1). Taken together, these data
indicate functional hypoxic signaling in H1339 cells although HIF-
1a expression was not affected.
As expected, Hsp90 inhibition caused a significant down-
regulation of hypoxia-induced HIF-1a levels from 8 to 24 h after
exposure to 17-AAG in EPLC-272H cells (Fig. 1A, grey bars, left
graph; *p#0.05, ***p#0.001). In H1339 cells, however, the
elevated basal HIF-1a levels were further up-regulated 24 h after
treatment with 17-AAG under normoxic and hypoxic conditions
(Fig. 1A, grey bars, right graph; *p#0.05, **p#0.01). Similar
results were obtained by using the small molecule Hsp90 inhibitor
NVP-AUY922 (Fig. 2B).
The administration of 17-AAG (100 nM; Fig. 1B) and NVP-
AUY922 (data not shown) did not significantly affect the HIF-2a
levels in both cell lines. These results suggest that stabilization of
HIF-2a in the two cell lines investigated might be regulated by a
mechanism which differs from that of HIF-1a.
The effectiveness of the Hsp90 inhibition by 17-AAG in EPLC-
272H and H1339 tumor cells under normoxic and hypoxic
conditions was proven by a strong induction of the synthesis of
Hsp70 (Fig. 1C). It is well established that Hsp90 inhibitors
stimulate the activity of heat shock factor 1 (HSF1), a transcription
factor which is essential for the induction of the Hsp70 expression.
Therefore, up-regulation of the cytosolic Hsp70 levels provides a
surrogate marker for functional Hsp90 inhibition [15]. Hsp90
inhibition was also demonstrated by the down-regulation of the
Hsp90 client protein AKT in both cell lines by a 24 h 17-AAG
treatment (Fig. 1C).
Since most prominent differences with respect to HIF-1a were
measured 24 h after 17-AAG treatment (Fig. 1A), further dose
response analyses were performed at this time-point. Drug-
induced toxicity could be excluded since a treatment of tumor
cells with 100 and 1000 nM 17-AAG or NVP-AUY922 for 24 h
did not reduce cell viability (Table S1).
HIF-1a levels were significantly down-regulated in normoxic
and hypoxic EPLC-272H cells by 17-AAG (Fig. 2A, left panel) and
NVP-AUY922 (Fig. 2B, left panel) at inhibitor concentrations of
100 and 1000 nM. In contrast, the same concentrations of 17-
AAG (Fig. 2A, right panel) and NVP-AUY922 (Fig. 2B, right
panel) induced an up-regulation of HIF-1a in normoxic and
hypoxic H1339 cells. These results derived by ELISA were
confirmed by Western blot analysis (Fig. 2C). Since a similar HIF-
1a expression pattern was observed using two structurally distinct
Hsp90 inhibitors, we conclude that HIF-1a regulation rather
depends on the tumor cell type than on the chemical structure of
the Hsp90 inhibitor.
In order to explain the differential regulation of HIF-1a after
treatment with Hsp90 inhibitors in H1339 and EPLC-272H lung
cancer cells, we investigated the expression of Cullin 5 E3
ubiquitin ligase (Cul5), receptor of activated protein C kinase
(RACK1) and Copper Metabolism MURR1 Domain containing 1
protein (COMMD1) which have been described to regulate the
degradation of HIF-1a upon Hsp90 inhibition [16–18]. As shown
in Figure 2D, the lung carcinoma cell lines with differential HIF-
1a expression did not differ in the expression pattern of these
proteins.
17-AAG and NVP-AUY922 differentially affect HIF-1a
target gene products in lung cancer cells
In order to determine how Hsp90 inhibition influences down-
stream HIF target gene products, the expression levels of carbonic
anhydrase IX (CA IX) and plasminogen activator inhibitor type-1
(PAI-1) were investigated following treatment with 17-AAG or
NVP-AUY922. CA IX is known to be regulated by HIF-1a [19],
whereas PAI-1 is described to be controlled by HIF-1a and/or
HIF-2a [20–22]. Hypoxia causes a strong induction of CA IX and
PAI-1 expression in EPLC-272H cells, which was down-regulated
after addition of increasing concentrations of 17-AAG or NVP-
AUY922 (Fig. 3A, left). In contrast to EPLC-272H cells, H1339
cells show similar CA IX levels under normoxia and hypoxia
which are increased by 17-AAG or NVP-AUY922 (Fig. 3A, right).
The same pattern was observed for HIF-1a levels (Fig. 2A–C)
suggesting that Hsp90 inhibition modulates CA IX levels in
H1339 cells via HIF-1a. PAI-1 expression of H1339 cells is
HIF-1a and Radiosensitization by Hsp90 Inhibitors
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was used as loading control since it has been shown to be a suitable
housekeeping gene under hypoxic conditions (Fig. S2) [23].
17-AAG- and NVP-AUY922-induced HIF-1a is functional
in H1339 lung cancer cells
The functionality of the increased HIF-1a proteins in H1339
cells upon Hsp90 inhibition was proven by measuring down-
stream target gene products, such as CA IX and PAI-1 after HIF-
1a knock-down. As shown in Fig. 3B, HIF-1a expression is
specifically inhibited by HIF-1a siRNA, whereas the HIF-2a levels
remained unaffected and vice versa. A mixture of HIF-1a and
HIF-2a siRNA resulted in a reduction of both HIF-a subunits
(Fig. 3B).
The expression of CA IX was specifically inhibited by
transfection with HIF-1a but not HIF-2a siRNA (Fig. 3B). A
simultaneous knock-down of HIF-1a and HIF-2a caused a
decrease in CA IX expression which is comparable to the
individual HIF-1a knock-down. In contrast to CA IX, PAI-1
expression was reduced by HIF-2a, but not by HIF-1a siRNA.
Figure 1. Time kinetics of HIF-1a, HIF-2a and Hsp70 levels after treatment with 17-AAG and exposure to hypoxia. (A) HIF-1a
expression levels in EPLC-272H (left panel) and H1339 (right panel) cells treated with 17-AAG and subsequently (30 min later) exposed to normoxia
for 24 h (24 h N) or hypoxia for 2 h (2 h H), 8 h (8 h H), 16 h (16 h H) and 24 h (24 h H) were determined by ELISA. Mean values 6 SEM of at least
three independent experiments are shown. *p#0.05, **p#0.01, ***p#0.001. (B and C) Representative HIF-2a (B), Hsp70 and AKT (C) immunoblots of
EPLC-272H and H1339 cells treated with 17-AAG and subsequently (30 min later) exposed to normoxia for 24 h (24 h N) or hypoxia for 2 h (2 h H),
8 h (8 h H), 16 h (16 h H) and 24 h (24 h H).
doi:10.1371/journal.pone.0031110.g001
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PLoS ONE | www.plosone.org 3 February 2012 | Volume 7 | Issue 2 | e31110Figure 2. 17-AAG and NVP-AUY922 enhance HIF-1a levels in H1339 lung cancer cells. (A and B) HIF-1a expression levels in EPLC-272H and
H1339 cells treated with 0, 100 and 1000 nM 17-AAG (A) or with 0, 100 and 1000 nM NVP-AUY922 (B) and subsequently (30 min later) exposed to
normoxia for 24 h (24 h N) or hypoxia for 24 h (24 h H) were determined by ELISA. Mean values 6 SEM of at least three independent experiments are
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PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e31110Furthermore, sequencing of the HIF-1a cDNA of H1339 lung
cancer cells revealed no changes to the published HIF-1a coding
sequence (NCBI Reference Sequence: NM_001530.3). These data
demonstrate that the Hsp90 inhibitor-induced HIF-1a levels were
not mutated and functional in H1339 cells, since CA IX is down-
regulated by a HIF-1a knock-down.
shown. *p#0.05, **p#0.01, ***p#0.001. (C) Representative HIF-1a immunoblots of EPLC-272H and H1339 cells treated with 0, 100 and 1000 nM 17-
AAG and subsequently (30 min later) exposed to normoxia for 24 h (24 h N) or to hypoxia for 24 h (24 h H). (D) Representative HIF-1a, Cul5, RACK1
and COMMD1 immunoblots of EPLC-272H and H1339 cells treated with 0 and 1000 nM NVP-AUY922 and subsequently (30 min later) exposed to
normoxia for 24 h (24 h N) or to hypoxia for 24 h (24 h H).
doi:10.1371/journal.pone.0031110.g002
Figure 3. 17-AAG- or NVP-AUY922- induced HIF-1a levels in H1339 lung cancer cells are functional. (A) Representative CA IX and PAI-1
immunoblots of EPLC-272H and H1339 cells treated with 0, 100 and 1000 nM 17-AAG or NVP-AUY922 and 30 min later exposed to normoxic (24 h N)
or hypoxic (24 h H) conditions for 24 h. The protein bands were quantified by densitometry using ImageJ. Numbers under the lanes represent the
expression of CA IX or PAI-1 relative to GAPDH. The value of 24 h hypoxia (24 h H) without drug treatment (0 nM) was set as 1 for each experiment.
(B) Representative HIF-1a, HIF-2a, CA IX and PAI-1 immunoblots of H1339 cells transfected with a non-targeting (ctrl), HIF-1a, HIF-2a or both HIF-1a
and HIF-2a siRNA. At 24 h after transfection, cells were treated with 100 nM 17-AAG or NVP-AUY922 and 30 min later exposed to normoxic (24 h N)
or hypoxic (24 h H) conditions for 24 h. The protein bands were quantified by densitometry using ImageJ. Numbers under the lanes represent the
expression of HIF-1a, HIF-2a, CA IX or PAI-1 relative to GAPDH. The value of 24 h hypoxia (24 h H) transfected with non-targeting siRNA (ctrl) was set
as 1 for each experiment.
doi:10.1371/journal.pone.0031110.g003
HIF-1a and Radiosensitization by Hsp90 Inhibitors
PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e31110Hsp90 inhibition enhances radiosensitivity of H1339 cells
regardless of HIF-1a levels
Based on low basal levels of HIF-1a in EPLC-272H and high
levels in H1339 tumor cells, a higher sensitivity towards Hsp90
inhibition was expected for EPLC-272H cells. However, the
sensitivity towards drug alone was comparable for both tumor cell
lines, whereby NVP-AUY922 (IC50: 2.5 nM for H1339; 2.0 nM
for EPLC-272H) was 15-times more effective than 17-AAG (IC50:
30.8 nM for H1339; 30.0 nM for EPLC-272H) (Fig. 4). Despite
varying HIF-1a levels, tumor cell lines EPLC-272H and H1339
also showed a comparable resistance towards irradiation (SF2: 0.64
for EPLC-272 and 0.76 for H1339). Although elevated HIF-1a
levels were previously reported to be predictive for radioresistance
[11] our findings show an increased radiosensitivity in tumors with
high basal HIF-1a levels. This finding was confirmed in a larger
panel of tumor cell lines derived from different entities [24].
Based on the differences in the IC50 values of the two drugs,
both tumor cell lines were treated for 24 h with 5, 10 and 20 nM
17-AAG, or 1 and 2 nM NVP-AUY922 in a combined treatment
with irradiation (0, 2, 4 and 6 Gy). Under normoxic conditions the
clonogenic survival curves of EPLC-272H cells revealed no
significant differences in radiosensitivity in the presence or absence
of 17-AAG or NVP-AUY922 (Fig. 5A, left panel). To our surprise,
radiosensitivity of H1339 cells was significantly increased after
treatment either with 20 nM 17-AAG (p=0.003 at 2 Gy;
p=0.007 at 4 Gy) or 2 nM NVP-AUY922 (p=0.008 at 4 Gy;
p=0.004 at 6 Gy) (Fig. 5A, right panel). As already shown for
drug only experiments (Fig. 4), a 10-fold lower concentration of
NVP-AUY922 (2 nM) resulted in the same radiosensitization
observed for 17-AAG (20 nM) in H1339 cells. The effects that
were seen in clonogenic assays with low drug concentrations could
be confirmed at high concentrations (Fig. S3).
We have shown that hypoxia differentially regulates HIF-1a
levels and its target gene products PAI-1 and CA IX in H1339 and
EPLC-272H cells (Figs. 1 and 3). Furthermore, hypoxia can
modulate the proteome of tumor cells via the HIF signaling and
can cause a more aggressive and radioresistant phenotype [25].
Most importantly, the group of Dewhirst demonstrated that
exposure to hypoxia before irradiation influences radiosensitivity
and that this effect is HIF-1a dependent [26]. Therefore, we
investigated whether 17-AAG- or NVP-AUY922-induced changes
in HIF-1a levels determine the radiosensitivity of the tumor cells
exposed to hypoxic conditions ([O2]=0.66%) prior to irradiation.
Similar to normoxia, the dose-response curves showed no
significant effect of 17-AAG or NVP-AUY922 on the radiosen-
sitivity of hypoxic EPLC-272H cells with a down-regulated HIF-
1a expression (Fig. 5B, left panel). In contrast, hypoxic H1339 cells
with significantly elevated HIF-1a levels showed a dramatic
increase in their radiosensitivity upon treatment with 17-AAG
(p=0.040 at 2 Gy; p=0.021 at 4 Gy) and NVP-AUY922 (Fig. 5B,
right panel).
A thorough analysis of radiobiological parameters confirmed
the radiosensitization in H1339 cells treated with 10 and 20 nM
17-AAG or 2 nM NVP-AUY922 under normoxic and hypoxic
conditions (Table S2).
To investigate the impact of the Hsp90 inhibitor-induced
elevated HIF-1a levels on the radiosensitivity of H1339 cells, HIF-
1a expression was down-regulated by a specific siRNA at the time
of irradiation (Fig. 6A). EPLC-272H cells in which HIF-1a is
induced by hypoxia but not by Hsp90 inhibition were used as a
control. In the absence of HIF-1a, radiosensitivity of normoxic
and hypoxic EPLC-272H and H1339 cells was not significantly
influenced (Fig. 6B). Independently of the HIF-1a status the
radiosensitivity of EPLC-272H cells could not be enhanced by 17-
AAG treatment (Fig. 6B). However, treatment with 17-AAG
(20 nM) significantly sensitized normoxic as well as hypoxic
H1339 cells towards irradiation, regardless of their intrinsic HIF-
1a levels. These data indicate that Hsp90 inhibition increases
radiosensitivity of H1339 lung cancer cells in a HIF-1a-
independent manner.
Discussion
Since hypoxia poses a major problem for the efficacy of
radiotherapy in lung cancer patients, the radiosensitizing capacity
of a novel (NVP-AUY922) and an established (17-AAG) Hsp90
inhibitor was analyzed in human lung carcinoma cell lines under
normoxic and hypoxic conditions and at clinically relevant, low
concentrations. In previous studies these effects were studied only
under normoxia and at high inhibitor concentrations [10,27–30].
In general, Hsp90 inhibitor-induced effects on the regulation of
hypoxia inducible genes are still a matter of debate. Ibrahim et al.
[31] described a 17-AAG-induced up-regulation of HIF-1a at low
(5–30 nM) and a down-regulation at high inhibitor concentrations
(1000–3000 nM). An oxygen- and VHL/PHD-independent ubi-
quitination and proteasomal degradation of HIF-1a was observed
after incubation of tumor cells with geldanamycin [32–34] and the
Figure 4. EPLC-272H and H1339 lung cancer cell lines show
similar drug-sensitivity. EPLC-272H and H1339 cells were exposed to
vehicle control (0 nM), 17-AAG (5–50 nM) or NVP-AUY922 (1–3.75 nM).
Drugs were present until fixation of colonies. The survival fraction was
calculated relative to the untreated control. Horizontal lines indicate
50% survival fraction. Mean values 6 SEM of at least 4 independent
experiments are shown.
doi:10.1371/journal.pone.0031110.g004
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PLoS ONE | www.plosone.org 6 February 2012 | Volume 7 | Issue 2 | e31110Figure 5. Hsp90 inhibitors increase radiosensitivity of H1339 lung cancer cells under normoxic and hypoxic conditions. EPLC-272H
and H1339 cells were treated with 17-AAG (5, 10, 20 nM) or NVP-AUY922 (1, 2 nM)) or vehicle control (0 nM), 30 min later exposed to normoxic (A) or
hypoxic (B) conditions for 24 h and, after 5 min of reoxygenation, irradiated with increasing doses of x-rays. Drugs were present until fixation of
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HIF-1a levels in human tumor xenografts [35]. In line with these
findings, upon treatment with 17-AAG and NVP-AUY922, basal as
well as hypoxia-induced HIF-1a levels were found to be decreased
in normoxic and hypoxic EPLC-272H cells at any tested
concentration. In contrast, H1339 tumor cells show an up-regulated
HIF-1a expression upon Hsp90 inhibition, irrespectively of the
inhibitor concentration and oxygenation status.
A dual role has been shown for Hsp70, on the one hand Hsp70
can protect HIF-1a from Hsp90 inhibitor induced degradation
[36] and on the other hand Hsp70 has been found to contribute to
the Hsp90 inhibitor induced degradation of HIF-1a [16].
However, no significant differences were found in the Hsp70
induction upon Hsp90 inhibition in H1339 and EPLC-272H cells,
with differential HIF-1a expression. Therefore, it was assumed
that genetic alterations in oncogenes and/or tumor suppressor
genes might be involved in the tumor cell type-specific regulation
of HIF-1a. Receptor of activated protein C kinase (RACK1)
competes with Hsp90 for binding to the Per/ARNT/Sim (PAS) -A
domain of HIF-1a and is required for Hsp90 inhibitor-induced
degradation of HIF-1a [17]. However, H1339 and EPLC-272H
tumor cells express similar amounts of RACK1 and also sequence
analysis did not reveal any mutations in the PAS-A domain of
HIF-1a in H1339 cells.
Cullin 5 E3 ubiquitin ligase (Cul5) and the Copper Metabolism
MURR1 Domain containing 1 protein (COMMD1) have recently
been reported to play key roles in the Hsp90 inhibitor-induced
degradation of HIF-1a [16–18]. Most notably, COMMD1 and
Cul5 expression was found to be decreased or lost in a number of
human tumors [37,38]. However, with respect to the expression
pattern of these proteins upon Hsp90 inhibition, no differences
were detectable in H1339 and EPLC-272H tumor cells.
Apart from HIF-1a, other HIF-a-subunits interact with Hsp90
[5]. In HIF-2a stably transfected Chinese hamster ovary (CHO)
cells, a treatment with geldanamycin caused a down-regulation of
HIF-2a [39]. We found that basal and hypoxia-induced naturally
occurring HIF-2a levels in EPLC-272H and H1339 lung cancer
cells remained unaltered following incubation with 17-AAG and
NVP-AUY922. The different results might be explained by the
fact that CHO cells are stably transfected with HIF-2a, whereas
the human lung cancer cell lines endogenously express HIF-2a.
The lung cancer cell lines EPLC-272H and H1339 were chosen
because they differ in their basal HIF-1a levels but show
comparable intrinsic resistance towards irradiation or drug alone.
Upon Hsp90 inhibition, HIF-1a levels were further elevated in
H1339 cells, whereas, normoxic and hypoxic EPLC-272H cells
reacted as expected with a reduction of HIF-1a.
Since high HIF-1 activity has been linked to radioresistance
[11,12,40–42], an Hsp90 inhibitor driven radiosensitization has been
expected for EPLC-272H cells with decreased HIF-1a levels. To our
surprise, radiosensitization was only observed in H1339 cells
expressing high HIF-1a levels upon Hsp90 inhibition under normoxic
and hypoxic conditions. An intrinsic tolerance of EPLC-272H cells to
Hsp90 inhibitors could be excluded since both lung cancer cell lines
showed a comparable up-regulation of Hsp70 – a surrogate marker
for Hsp90 inhibition - and a similar sensitivity towards drug alone.
However, dual effects of HIF-1a in regulating tumor cell
survival have been described [26]. On the one hand, HIF-1a can
exert pro-survival functions, e.g., by the inhibition of apoptosis, on
the other hand, HIF-1a can increase apoptosis, enhance glycolysis
and induce mitosis in tumor cells, all factors leading to increased
radiosensitivity [43–46]. Therefore, the balance of these opposing
effects may determine whether or not HIF-1a has an effect on
radiosensitivity.
In summary, our data reveal that radiosensitization of tumor
cells by Hsp90 inhibitors is independent of basal and Hsp90
inhibitor-induced HIF-1a levels.
Materials and Methods
Reagents
10 mM stock solutions of 17-AAG (Sigma, Taufkirchen,
Germany) and NVP-AUY922 (Novartis, Basel, Switzerland) were
prepared in 100% DMSO and aliquots stored at 220uC. Further
dilutions were performed in PBS. A vehicle control with the
respective amount of DMSO diluted in PBS (0.00001%–0.01%
DMSO o 1 nM–1000 nM NVP-AUY922 or 17-AAG) was tested
in all experiments to exclude an effect of DMSO itself.
Cells and cell culture
Human lung cancer cell lines, H1339 (SCLC) and EPLC-272H
(NSCLC) (kindly provided by Prof. Rudolf Huber, Department of
Pneumology, University of Munich, Munich, Germany) were
cultured in RPMI 1640 (Invitrogen, San Diego, CA) supplemented
with 10% v/v heat-inactivated FCS (PAA, Pasching, Austria),
100 IU/ml penicillin, 100 mg/ml streptomycin, 2 mM L-gluta-
mine, and 1 mM sodium pyruvate (Life Technologies, Eggenstein,
Germany). Cells were routinely checked and determined as
negative for mycoplasma contamination.
Hypoxia
Cells were incubated for various time periods (2, 8, 16 and 24 h)
under hypoxic conditions ([O2]=0.66%) at 37uC. Hypoxic
conditions were achieved as described previously [47].
ELISA and Western blot analysis
Attached cells were lysed in TBST buffer (1% Triton X-100 in
TBS, 1 mM PMSF, protease inhibitor cocktail) as described
previously [48]. Protein content in the cell lysates was determined
using the BCA
TM Protein Assay Kit (Pierce, Rockford, IL).
HIF-1a concentrations in cell lysates (R & D Systems,
Minneapolis, MN) were determined by ELISA according to the
manufacturer’s instructions. HIF-1a concentrations were calculated
relative to the total protein content of each sample. For the
calculation of relative levels, the untreated control was set at 100%.
For Western Blot analysis, proteins were separated by SDS-
PAGE under reducing conditions as previously described [49],
blotted onto PVDF membranes and detected with monoclonal
antibodies directed against HIF-1a (R & D Systems, Minneapolis,
MN), Hsp70 (SPA-810, Assay Designs, Ann Arbor, MI), RACK1
(BD, NJ, USA), COMMD1 (Abnova, Taipei City, Taiwan),
GAPDH (Sigma-Aldrich, Taufkirchen, Germany), b-actin (Sigma-
Aldrich, Taufkirchen, Germany) and polyclonal antibodies
directed against HIF-2a (abcam, Cambridge, UK), AKT (Cell
Signaling, MA, USA), Cul5 (Millipore, MA; USA), CA IX
colonies. The survival fractions were calculated after normalization for cell kill by 17-AAG or NVP-AUY922 alone. The pre-incubation under hypoxia for
24 h had no significant influence on the survival fraction (H1339: 9463.6%; EPLC-272H: 10065.3%). Mean values 6 SEM of at least 4 independent
experiments are shown. Significant differences between vehicle control and cells treated with 20 nM 17-AAG or 2 nM NVP-AUY922 are indicated
(*p#0.05, **p#0.01). Survival curves were fitted to the linear quadratic model.
doi:10.1371/journal.pone.0031110.g005
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PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e31110Figure 6. Radiosensitization of H1339 lung cancer cells by 17-AAG is independent of HIF-1a. EPLC-272H and H1339 cells were
transfected with non-targeting (ctrl) or HIF-1a siRNA. At 48 h after transfection, cells were treated with vehicle control (0 nM) or 20 nM 17-AAG,
30 min later exposed to normoxic or hypoxic conditions for 24 h and, after 5 min of reoxygenation, irradiated with increasing doses of x-rays. (A)
Knock-down of HIF-1a at the time of irradiation is shown by immunoblot. (B) The survival fractions were calculated after normalization for cell kill by
17-AAG alone. 17-AAG was present until fixation of colonies. Mean values 6 SEM of 4 independent experiments are shown. Significant differences
between vehicle control and cells treated with 20 nM 17-AAG are indicated (*p#0.05, **p#0.01). Survival curves were fitted to the linear quadratic
model.
doi:10.1371/journal.pone.0031110.g006
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Prof. Sweep, Department of Chemical Endocrinology, Radboud
University Nijmegen Medical Center, Nijmegen, Netherlands).
Bound antibodies were visualized using horseradish peroxidise-
conjugated secondary antibodies (Promega, Madison, WI) and a
chemiluminescence developing kit (ECL, Amersham Biosciences,
Buckinghamshire, UK). The protein bands were quantified by
densitometry using ImageJ.
Transfection with siRNA
Cells were transfected with 5 nM siRNA duplexes (Qiagen,
Hilden, Germany) to either a non-targeting sequence (allstars
negative control), to HIF-1a (AGGAAGAACTATGAACA-
TAAA), to HIF-2a (CCCGGATAGACTTATTGCCAA) or to
both HIF-1a and HIF-2a using the HiPerfect Transfection
Reagent (Qiagen, Hilden, Germany).
Clonogenic cell survival assay and irradiation
Tumor cells were seeded into 12-well plates. Cells were treated
with 17-AAG or NVP-AUY922, exposed to hypoxia or normoxia
and/or irradiated. Cells were irradiated with the indicated doses
using the RS225A irradiation device (Gulmay Medical Ltd., UK)
at a dose rate of 1 Gy/min (70 keV). Irradiations were performed
under atmospheric conditions ([O2]=21%). On day 7–10 after
seeding, colonies were fixed in methanol, stained with crystal violet
and counted. Survival curves were fitted to the linear quadratic
model using Sigmaplot (Systat Software Inc, San Jose, CA).
Statistics
Statistical analysis was performed using SPSS 18.0.2 software.
The Student’s t-test was used to evaluate significant differences
(*p#0.05, **p#0.01, ***p#0.001).
Supporting Information
Figure S1 Hypoxia induced G1-arrest in H1339 cells.
Following normoxia (24 h N) or hypoxia (24 h H) for 24 h, cells
were harvested. After washing in PBS and fixation (70% ethanol
over night; 220uC), cells were incubated in PI staining solution
(PBS containing 0.1% Triton X-100, 0.2 mg/ml RNase A,
0.02 mg/ml PI) for 1 h at room temperature and analyzed on a
FACSCalibur flow cytometer (BD Biosciences, San Jose, CA,
USA). Cell cycle distribution was determined using ModFit LT
(Verity Software House, Topsham, ME). Data represent mean
values 6 SEM of three independent experiments. After hypoxia
G1-phase was significantly (*** p#0.001) increased and S-phase
significantly (*** p#0.001) reduced.
(TIFF)
Figure S2 GAPDH and b-actin are comparable loading
controls in normoxic and hypoxic EPLC-272H and
H1339 tumor cells. Following treatment (30 min) with 0, 100
and1000 nM17-AAG,EPLC-272H and H1339cellswereexposed
to normoxia (24 h N) or hypoxia (24 h H) for 24 h. The expression
of GAPDH and ß-actin was comparable in untreated and 17-AAG-
treated cells under normoxic and hypoxic conditions. Similar results
were obtained for NVP-AUY922 (data not shown).
(TIF)
Figure S3 Radiosensitivity of EPLC-272H and H1339
cells after treatment with high concentrations of 17-
AAG. 24 h after treatment of EPLC-272H and H1339 tumor cells
with 100 nM 17-AAG or vehicle control (0 nM), cells were
irradiated with increasing doses of x-rays. 17-AAG was removed
1 h after irradiation. The survival fractions were calculated after
normalization for cell kill by 17-AAG alone. Data represent mean
values 6 SEM of at least 3 independent experiments. Significant
differences between vehicle control and cells treated with 100 nM
17-AAG are indicated (*p#0.05, **p#0.01). Survival curves were
fitted to the linear quadratic model.
(TIFF)
Table S1 Percentage of viable cells treated for 24 h with
17-AAG or NVP-AUY922. Following a 24 h treatment with 17-
AAG or NVP-AUY922, cells were washed and stained with propidium
iodide (PI) for 1 min. Viable cells (PI negative) were analyzed on a
FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA).
Mean values 6 SEM of four independent experiments are shown.
(DOC)
Table S2 Summary of radiobiological parameters cal-
culated from Fig. 5. SF2, survival fraction at 2 Gy. D50,d o s et o
reduce survival fraction to 50%. Sensitizing enhancement ratio
(SER)=D50 (irradiation)/D50 (irradiation and drug). A SER greater
than 1.20 is indicative for radiosensi t i z a t i o n( i n d i c a t e di nb o l d ) .M e a n
values 6 SEM of at least four independent experiments are shown.
(DOC)
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